(RMD) ResMed - Overview
Stock: Sleep apnea devices, Ventilators, Home care software, SaaS dashboards
| Risk 5d forecast | |
|---|---|
| Volatility | 31.9% |
| Relative Tail Risk | -9.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | -1.48 |
| Character TTM | |
|---|---|
| Beta | 0.616 |
| Beta Downside | 0.472 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.87% |
| CAGR/Max DD | 0.17 |
EPS (Earnings per Share)
Revenue
Description: RMD ResMed January 28, 2026
ResMed Inc. (NYSE:RMD) designs, manufactures, and markets medical-device hardware and cloud-based software for diagnosing, treating, and managing respiratory disorders. The business is split between a Sleep & Breathing Health segment-offering home- and clinic-based sleep-apnea diagnostics (e.g., ApneaLink Air, NightOwl) and connected therapy platforms (AirView, myAir)-and a Residential Care Software segment that supplies EHR, billing and analytics solutions (Brightree, HEALTHCAREfirst, MatrixCare, MEDIFOX DAN) to home-health, hospice and senior-living providers.
In its most recent fiscal year (2023), ResMed reported revenue of $3.22 billion, up ≈ 9 % year-over-year, with operating income of $483 million (≈ 15 % margin). Cloud-based subscription revenue grew 18 % YoY, reflecting expanding adoption of AirView and myAir, while device shipments rose 12 % driven by the NightOwl portable diagnostic. The company’s R&D spend remained steady at ~ $380 million (≈ 12 % of revenue), underscoring continued investment in connected-care technology.
Key growth catalysts include the aging U.S. population (the 65+ cohort is projected to reach 21 % of the population by 2035) and the high prevalence of sleep-apnea-estimated at 26 % of adults-fueling demand for home-based diagnostics and remote-monitoring solutions. Macro-level drivers such as expanding telehealth reimbursement, favorable Medicare policies for home-use devices, and broader healthcare-equipment spending trends also support ResMed’s outlook. However, potential headwinds remain: tighter reimbursement rates or regulatory changes could compress margins, and competitive pressure from emerging low-cost diagnostic entrants could affect market share.
For a deeper quantitative assessment of RMD’s valuation and risk profile, consider reviewing the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 1.59 > 1.0 |
| NWC/Revenue: 47.62% < 20% (prev 40.27%; Δ 7.35% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.91b > Net Income 1.49b |
| Net Debt (-415.2m) to EBITDA (2.07b): -0.20 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (147.0m) vs 12m ago -0.38% < -2% |
| Gross Margin: 60.98% > 18% (prev 0.58%; Δ 6040 % > 0.5%) |
| Asset Turnover: 69.01% > 50% (prev 68.99%; Δ 0.02% > 0%) |
| Interest Coverage Ratio: 71.47 > 6 (EBITDA TTM 2.07b / Interest Expense TTM 25.7m) |
Altman Z'' 9.29
| A: 0.30 (Total Current Assets 3.82b - Total Current Liabilities 1.25b) / Total Assets 8.50b |
| B: 0.78 (Retained Earnings 6.65b / Total Assets 8.50b) |
| C: 0.23 (EBIT TTM 1.84b / Avg Total Assets 7.82b) |
| D: 3.03 (Book Value of Equity 6.62b / Total Liabilities 2.18b) |
| Altman-Z'' Score: 9.29 = AAA |
Beneish M -3.16
| DSRI: 0.94 (Receivables 985.6m/959.8m, Revenue 5.40b/4.93b) |
| GMI: 0.95 (GM 60.98% / 57.94%) |
| AQI: 0.91 (AQ_t 0.47 / AQ_t-1 0.51) |
| SGI: 1.10 (Revenue 5.40b / 4.93b) |
| TATA: -0.05 (NI 1.49b - CFO 1.91b) / TA 8.50b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of RMD shares?
Over the past week, the price has changed by -1.30%, over one month by +0.69%, over three months by +3.09% and over the past year by +10.32%.
Is RMD a buy, sell or hold?
- StrongBuy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the RMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 297.5 | 14.6% |
| Analysts Target Price | 297.5 | 14.6% |
| ValueRay Target Price | 269.5 | 3.8% |
RMD Fundamental Data Overview February 12, 2026
P/E Forward = 23.9234
P/S = 7.2211
P/B = 6.0621
P/EG = 1.7406
Revenue TTM = 5.40b USD
EBIT TTM = 1.84b USD
EBITDA TTM = 2.07b USD
Long Term Debt = 403.9m USD (from longTermDebt, last quarter)
Short Term Debt = 289.7m USD (from shortTermDebt, last quarter)
Debt = 1.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -415.2m USD (from netDebt column, last quarter)
Enterprise Value = 38.57b USD (38.98b + Debt 1.00b - CCE 1.42b)
Interest Coverage Ratio = 71.47 (Ebit TTM 1.84b / Interest Expense TTM 25.7m)
EV/FCF = 21.56x (Enterprise Value 38.57b / FCF TTM 1.79b)
FCF Yield = 4.64% (FCF TTM 1.79b / Enterprise Value 38.57b)
FCF Margin = 33.13% (FCF TTM 1.79b / Revenue TTM 5.40b)
Net Margin = 27.53% (Net Income TTM 1.49b / Revenue TTM 5.40b)
Gross Margin = 60.98% ((Revenue TTM 5.40b - Cost of Revenue TTM 2.11b) / Revenue TTM)
Gross Margin QoQ = 62.18% (prev 61.46%)
Tobins Q-Ratio = 4.54 (Enterprise Value 38.57b / Total Assets 8.50b)
Interest Expense / Debt = 0.79% (Interest Expense 7.95m / Debt 1.00b)
Taxrate = 20.87% (103.6m / 496.1m)
NOPAT = 1.45b (EBIT 1.84b * (1 - 20.87%))
Current Ratio = 3.06 (Total Current Assets 3.82b / Total Current Liabilities 1.25b)
Debt / Equity = 0.16 (Debt 1.00b / totalStockholderEquity, last quarter 6.32b)
Debt / EBITDA = -0.20 (Net Debt -415.2m / EBITDA 2.07b)
Debt / FCF = -0.23 (Net Debt -415.2m / FCF TTM 1.79b)
Total Stockholder Equity = 5.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.00% (Net Income 1.49b / Total Assets 8.50b)
RoE = 24.81% (Net Income TTM 1.49b / Total Stockholder Equity 5.99b)
RoCE = 28.71% (EBIT 1.84b / Capital Employed (Equity 5.99b + L.T.Debt 403.9m))
RoIC = 21.82% (NOPAT 1.45b / Invested Capital 6.66b)
WACC = 8.00% (E(38.98b)/V(39.98b) * Re(8.19%) + D(1.00b)/V(39.98b) * Rd(0.79%) * (1-Tc(0.21)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.17%
[DCF Debug] Terminal Value 81.26% ; FCFF base≈1.63b ; Y1≈2.01b ; Y5≈3.42b
Fair Price DCF = 399.7 (EV 57.81b - Net Debt -415.2m = Equity 58.23b / Shares 145.7m; r=8.00% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 96.31 | EPS CAGR: 22.32% | SUE: 1.21 | # QB: 1
Revenue Correlation: 96.75 | Revenue CAGR: 14.21% | SUE: 1.78 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.81 | Chg30d=+0.041 | Revisions Net=+10 | Analysts=13
EPS current Year (2026-06-30): EPS=11.03 | Chg30d=+0.124 | Revisions Net=+11 | Growth EPS=+15.5% | Growth Revenue=+9.7%
EPS next Year (2027-06-30): EPS=12.18 | Chg30d=+0.151 | Revisions Net=+15 | Growth EPS=+10.4% | Growth Revenue=+7.5%